PRDM2 and hepatocellular carcinoma: Abnormal methylation of the RASSF1, GSTP1, p14, CDH1, APC, RUNX3, SOCS1, p15, MGMT, SFRP1, WIF1, PRDM2, DAPK1, RARβ, hMLH1, p73, DLC1, p53, SPINT2, OPCML, and WT1 genes in the tumor tissues of HCC patients can be used as a marker to predict the incidence and survival rate of HCC patients [67].